| __timestamp | Agios Pharmaceuticals, Inc. | Bristol-Myers Squibb Company |
|---|---|---|
| Wednesday, January 1, 2014 | 19120000 | 5699000000 |
| Thursday, January 1, 2015 | 35992000 | 5001000000 |
| Friday, January 1, 2016 | 50714000 | 5002000000 |
| Sunday, January 1, 2017 | 71124000 | 4849000000 |
| Monday, January 1, 2018 | 114145000 | 4551000000 |
| Tuesday, January 1, 2019 | 132034000 | 4871000000 |
| Wednesday, January 1, 2020 | 149070000 | 7661000000 |
| Friday, January 1, 2021 | 121445000 | 7690000000 |
| Saturday, January 1, 2022 | 121673000 | 7814000000 |
| Sunday, January 1, 2023 | 119903000 | 7772000000 |
| Monday, January 1, 2024 | 156784000 | 8414000000 |
Igniting the spark of knowledge
In the ever-evolving pharmaceutical industry, operational efficiency is key to maintaining a competitive edge. Over the past decade, Bristol-Myers Squibb Company and Agios Pharmaceuticals, Inc. have demonstrated contrasting approaches to managing Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Bristol-Myers Squibb consistently allocated a significant portion of its budget to SG&A, peaking at approximately $7.8 billion in 2022. This reflects a strategic focus on robust marketing and administrative frameworks, essential for a global pharmaceutical giant.
Conversely, Agios Pharmaceuticals, a smaller player, saw its SG&A expenses grow from $19 million in 2014 to around $120 million in 2023, marking a substantial increase of over 500%. This growth underscores Agios's expansion efforts and its commitment to scaling operations. The data highlights the diverse strategies employed by these companies in navigating the complex pharmaceutical landscape.
Breaking Down SG&A Expenses: Eli Lilly and Company vs Agios Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Johnson & Johnson and Bristol-Myers Squibb Company
Bristol-Myers Squibb Company or Zoetis Inc.: Who Manages SG&A Costs Better?
Bristol-Myers Squibb Company or Vertex Pharmaceuticals Incorporated: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Neurocrine Biosciences, Inc.
Bristol-Myers Squibb Company and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Bristol-Myers Squibb Company or Dr. Reddy's Laboratories Limited: Who Manages SG&A Costs Better?
Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Pharming Group N.V. or Agios Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Xenon Pharmaceuticals Inc. and Agios Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Agios Pharmaceuticals, Inc. vs Wave Life Sciences Ltd.
Selling, General, and Administrative Costs: Agios Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc.